- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07705685
National Cohort Study on Infant Gut Microbiota and Nutrition
Study on Gut Microbiota Characteristics and Their Relationship With Nutritional Health in Infants and Young Children Based on a National Cohort
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The human gastrointestinal tract harbors vast and diverse microbial communities collectively termed the "gut microbiota", widely known as the human body's "second genome". Research has demonstrated that during the colonization and maturation of gut microbiota in early infancy, these microbes participate in multiple core physiological processes including immune system maturation, nutrient absorption and metabolism, and nervous system development. Infancy represents a critical window for the establishment of intestinal microecology. Disturbances from adverse environmental factors such as antibiotic administration, inappropriate dietary patterns, and environmental pollution may trigger dysbiosis of microbial composition, which in turn elevates the long-term risk of developing obesity, allergic disorders, asthma, autism spectrum disorders and other diseases.
The formation and dynamic shifts of childhood gut microbiota are shaped not only by early-life exposures including mode of delivery, breastfeeding status and antibiotic use, but also by subsequent dietary patterns, living environments and socioeconomic status. For instance, high-fat diets reduce the abundance of beneficial gut bacteria, whereas Mediterranean-style diets support intestinal health; antibiotic treatment markedly diminishes microbial diversity and impairs community stability; urban-rural disparities also drive profound differences in gut microbial composition.
To date, domestic research on gut microbiota among infants and children has largely consisted of regional, small-cohort studies, lacking large-scale baseline datasets covering diverse geographic regions, age brackets and health statuses across China. This gap partially hinders the accumulation of scientific evidence for pediatric intestinal health research and disease prevention and control, and restricts the formulation of localized nutritional intervention strategies.
Accordingly, this study aims to conduct a large-cohort investigation covering infants and children aged 0 to 6 years nationwide. Through metagenomic sequencing and microbial isolation and culture of fecal specimens, we will construct gut microbiota atlases stratified by age, geographic region and health profile. The research will focus on associations between representative core gut taxa (e.g., Bifidobacterium) and indicators including children's nutritional status, immune development, allergic manifestations, gastrointestinal function and physical growth. We will also characterize microbial succession patterns during critical developmental windows in early life. Multivariate modeling and machine learning algorithms will be applied to screen microbial biomarkers strongly correlated with specific health conditions, and further dissect their underlying biological mechanisms.
This project is led by a professional research team with extensive experience in intestinal microecology. The team has previously completed gut microbiota profiling and analysis for thousands of infant subjects, obtained ethical approval and secured third-party laboratory qualification, laying a solid research foundation. Findings from this study will provide data support for early identification and intervention of common childhood illnesses, and deliver vital scientific evidence for developing personalized nutritional and health management strategies tailored to gut microecological signatures in Chinese children.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
-
Shanghai, China
- DiPROBIO(Shanghai) Co., Ltd.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Infants and children aged 0-6 years, regardless of gender.
- Volunteers willing to participate in fecal sample collection and baseline health information gathering during the study period.
- Legal guardians must agree to participate in the study and provide a signed written informed consent.
Exclusion Criteria:
- Presence of congenital developmental anomalies, including but not limited to congenital cardiovascular malformations and chromosomal aneuploidy.
- Immune system functional disorders, such as Severe Combined Immunodeficiency.
- Diagnosis of hereditary diseases, such as genetic disorders caused by chromosomal abnormalities.
- Any condition deemed unsuitable for participation by the investigator, including but not limited to failure to meet compliance assessment standards.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
National cohort of Chinese children aged 0-6 years
This single nationwide cohort enrolls a total of 106,667 Chinese infants and children under 6 years old.
enrollment.
|
This study is purely observational with no therapeutic or invasive clinical interventions implemented.
We only collect non-invasive fecal specimens from enrolled healthy infants and children aged 0-6 years across China, perform microbial genome sequencing and microbial isolation culture to analyze gut microbiota characteristics, and construct a national pediatric gut microbiome atlas.
No drugs, medical devices or clinical treatment adjustments are given to participants throughout the research.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Establish a national gut microbiome atlas of infants and children aged 0-6 years covering all 34 provincial-level administrative regions in China, incorporating subjects across distinct age brackets and geographic backgrounds
Zeitfenster: Baseline (single time point at enrollment)
|
Baseline (single time point at enrollment)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Qinghua Yu, DiproBio (Shanghai) Co., Ltd.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- SECCR2025-158-01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fecal Gut Microbiota
-
National Institute of Rehabilitation, MexicoNoch keine Rekrutierung
-
TOPMEDNatural Sciences and Engineering Research Council, Canada; SEC Fonds Immobilier... und andere MitarbeiterAbgeschlossen
-
Nanyang Technological UniversityAbgeschlossen
-
University of MichiganMichigan Health Endowment FundAbgeschlossen
-
The University of Hong KongHealth and Medical Research FundAbgeschlossen
-
Suez Canal UniversityAbgeschlossen
-
TruDiagnosticBlushield USANoch keine Rekrutierung
-
Helse Stavanger HFEvonik Industries AGRekrutierungGesundes Altern | Gut alternNorwegen
-
Hong Kong Baptist UniversityAbgeschlossenKörperlich gut, aber besorgtHongkong